Apollomics (APLM) Receivables (2025)
Apollomics (APLM) posted quarterly Receivables of $2.3 million for Q4 2025, down 67.99% on a QoQ basis from $7.2 million in Q2 2025.
Apollomics (APLM) Receivables (2025) Analysis & Trends
Apollomics (APLM) has reported Receivables for 1 consecutive years, with $2.3 million the latest figure, recorded in Q4 2025.
- Quarterly Receivables changed N/A year-over-year to $2.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.3 million (changed N/A YoY) and the FY2025 annual result came in at $2.3 million, changed N/A from the prior year.
- Receivables retreated to $2.3 million in Q4 2025 per APLM's latest filing, from $7.2 million in the prior quarter.
- Over the last five years, Receivables for APLM reached as high as $7.2 million in Q2 2025 and fell as low as $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 4.97 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 938.02 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.13 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.00 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 5.73 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.93 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Apollomics | 2.66 Bn | 2.66 Bn | - | 2.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.31 Mn |
| Jun 30, 2025 | 7.20 Mn |